IDE Antibody

Code CSB-PA010988LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human gastric cancer using CSB-PA010988LA01HU at dilution of 1:100

  • Immunofluorescent analysis of HepG2 cells using CSB-PA010988LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) IDE Polyclonal antibody
Uniprot No.
Target Names
IDE
Alternative Names
Abeta-degrading protease antibody; FLJ35968 antibody; Ide antibody; IDE_HUMAN antibody; Insulin protease antibody; Insulin-degrading enzyme antibody; Insulinase antibody; Insulysin antibody; OTTHUMP00000020097 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Insulin-degrading enzyme protein (501-800AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The IDE Antibody (Product code: CSB-PA010988LA01HU) is Non-conjugated. For IDE Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA010988LB01HU IDE Antibody, HRP conjugated ELISA
FITC CSB-PA010988LC01HU IDE Antibody, FITC conjugated
Biotin CSB-PA010988LD01HU IDE Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a role in the cellular breakdown of insulin, APP peptides, IAPP peptides, natriuretic peptides, glucagon, bradykinin, kallidin, and other peptides, and thereby plays a role in intercellular peptide signaling. Substrate binding induces important conformation changes, making it possible to bind and degrade larger substrates, such as insulin. Contributes to the regulation of peptide hormone signaling cascades and regulation of blood glucose homeostasis via its role in the degradation of insulin, glucagon and IAPP. Plays a role in the degradation and clearance of APP-derived amyloidogenic peptides that are secreted by neurons and microglia (Probable). Degrades the natriuretic peptides ANP, BNP and CNP, inactivating their ability to raise intracellular cGMP. Also degrades an aberrant frameshifted 40-residue form of NPPA (fsNPPA) which is associated with familial atrial fibrillation in heterozygous patients. Involved in antigen processing. Produces both the N terminus and the C terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is presented to cytotoxic T lymphocytes by MHC class I.; (Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).
Gene References into Functions
  1. These results support the hypothesis that IDE gene expression in different areas of Alzheimer's patient's brains. PMID: 28164769
  2. People with allelic variation in four genes related to cardiovascular diseases and metabolism were more likely to die: apolipoprotein (APO)C1 GG and AG carriers, APOE varepsilon4 carriers, insulin-degrading enzyme (IDE) TC carriers, and phosphatidylinositol 3-kinase (PI3KCB) GG carriers. PMID: 27806189
  3. Data suggest the possibility of development of insulin-degrading enzyme (IDE)-based drugs for the treatment of the late-onset form of Alzheimer's disease (AD). PMID: 27982586
  4. the mechanistic and molecular features of IDE-26S proteasome interaction in a cell experimental model, is reported. PMID: 26186340
  5. No significant associations have been found between other IDE gene single nucleotide polymorphisms of rs4646953, rs2251101 and rs1544210 with Alzheimer disease. PMID: 25105907
  6. results demonstrate that the polymorphisms rs1887922 and rs1999764 of the IDE gene are associated with late-onset Alzheimer disease susceptibility in the Xinjiang Han population PMID: 25414272
  7. Cognitive impairment is more frequent among those exposed to the C allele of the rs2209972 SNP of the insulin degrading enzyme gene. PMID: 24355596
  8. IDE does not play a major role in MHC class I antigen processing, confirming the dominant and almost exclusive role of the proteasome in cytosolic production of MHC class I ligands. PMID: 24516642
  9. using combinational in silico investigations, study identified that pathogenic nonsynonymous mutations corresponding to p.I54F, p.P122T, p.T533R, p.P581A and p.Y609A have more potential role in structural and functional deviations of IDE activity PMID: 24059301
  10. Our study provided evidence to IDE, PON1, WFS1, POU2F1, IL1alpha and IL1beta associated with T2D in Pakistanis. PMID: 24477584
  11. An upstream promoter element which blocks the antisense transcription of the human IDE promoter, was identified. PMID: 23797320
  12. Both IDE and type 2 diabetes are associated with executive function levels in older adults PMID: 23597493
  13. Conformational changes in IDE, including a swinging-door mechanism that permits the entry of short peptides into the catalytic chamber, governs the selective destruction of amyloidogenic peptides. PMID: 23922390
  14. for the rs1832196 polymorphism, significant association with Alzheimer disease was found by the dominant model in overall and subgroup analysis. PMID: 23416320
  15. IDE-Met(1) links the mitochondrial biogenesis pathway with mitAbeta levels and organelle functionality. PMID: 23525105
  16. Genetic variants for both insulin degrading enzyme (IDE) and angiotensin converting enzyme (ACE) in relation to cognitive phenotype. PMID: 21232820
  17. In the context of APOEepsilon4-negative status, insulin-degrading enzyme variants are significantly associated with Alzheimer disease in some genetic models. PMID: 22502914
  18. The polymorphism of insulin-degrading enzyme is associated with susceptibility to Alzheimer's disease in Han Chinese. PMID: 20880607
  19. Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. PMID: 22267728
  20. The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Abeta42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic variant IDE9. PMID: 22107728
  21. Significant differences were found in the response to induced ketosis among non-carriers of putative gain-of-function polymorphisms in rs1143627 and rs16944 in the IL-1beta gene and among variants of the polymorphism rs2251101 in the insulysin gene. PMID: 21992747
  22. BRI2 protein regulates beta-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). PMID: 21873424
  23. Five IDE variants for altered in vitro reporter gene expression, based on their presence on haplotypes (H2, H6 and H9) and their association with altered IDE mRNA transcript levels , were tested. PMID: 21731745
  24. dimers of insulin-degrading enzyme reveal a cis activation mechanism PMID: 21343292
  25. IDE cleaves ubiquitin in a biphasic manner PMID: 21185309
  26. the evolutionarily conserved IDE may play a key role in modulating and reshaping the strength and duration of NP-mediated signaling. PMID: 21098034
  27. IIA(Glc) of the sugar phosphotransferase system regulates the peptidase activity of a mammalian insulysin homolog in V. vulnificus. PMID: 20971110
  28. Insulin degrading enzyme is linked with aggregated Abeta40 isoform while neprilysin negatively correlates with amyloid angiopathy. PMID: 19019493
  29. IDE is not correlated with amyloig beta or clinical diagnosis Alzheimer disease PMID: 20663017
  30. produce tumor antigenic peptides presented by MHC class I molecules for cytotoxic T lymphocyte recognition PMID: 20364150
  31. the catalytic mechanisms for the hydrolysis of the three different peptide bonds of Alzheimer amyloid beta (Abeta) peptide by insulin-degrading enzyme (IDE) PMID: 20033747
  32. this study more generally suggests an interplay between RB and IDE within the proteasome that may have important growth-regulatory consequences. PMID: 20362553
  33. Results describe the in vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme. PMID: 20082125
  34. In comparison to Abeta40, Abeta42 is more flexible and interacts through a smaller number (17-22) of hydrogen bonds in the catalytic chamber of IDE. PMID: 20380468
  35. a previously unreported variant unequivocally associated with increased IDE expression was also associated with reduced plasma Abeta40 and decreased LOAD susceptibility PMID: 20098734
  36. Study verified associations of two IDE polymorphisms (rs1887922 and rs2149632) with type 2 diabetes risk in two independent German cohorts and evaluated in detail the association of common variants with insulin metabolism and glycemic traits. PMID: 19809796
  37. structural basis of how the high dipole moment of substrates complements the charge distribution of the IDE catalytic chamber for the substrate selectivity PMID: 19896952
  38. IDE protease binds to the 73-kDa gE precursor and that this event occurs in the cytosol but not as a receptor/ligand interaction. PMID: 19864391
  39. possible mechanism by which the insulin-degrading enzyme (IDE) zinc-binding protease carries out its catalytic function toward two peptides of different length PMID: 19785409
  40. Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). PMID: 11809755
  41. analysis of over 2,400 samples provides no compelling evidence that variation in IDE contributes to diabetes susceptibility in humans PMID: 12716770
  42. when intracellular long-chain fatty acid concentrations are elevated, they may act directly on insulin-degrading enzyme to decrease insulin metabolism and alter insulin action in intact cells and this mechanism may contribute to insulin resistance PMID: 12746301
  43. Polymorphism in this enzyme are associated with NIDDM in men. PMID: 12765971
  44. IDE gene polymorphisms do not confer susceptibility to early- or late-onset AD at least in a Japanese population. PMID: 14755451
  45. Biochemical characteristics of insulin degradation in wound fluid were consistent with characteristics of insulin-degrading enzyme. Reduction in insulin-degrading activity in wound fluid is potential therapeutic target. PMID: 14764804
  46. genomic region in the proximity of IDE that may contribute to Alzheimer and Parkinson disease in a similar manner. PMID: 15088150
  47. IDE gene promoter region variants are associated with AD in subjects without an epsilon4 allele PMID: 15181249
  48. Polymorphism in/near IDE contributes to a large proportion of variance in plasma insulin levels and correlated traits. PMID: 15277398
  49. The C allele of single-nucleotide polymorphism IDE2 associated with Alzheimer disease. There may be a possible synergic interaction between IDE & APOE epsilon4. PMID: 15277615
  50. a defect in Abeta proteolysis by IDE contributes to the accumulation of this peptide in the cortical microvasculature PMID: 15489232

Show More

Hide All

Subcellular Location
Cytoplasm, cytosol. Cell membrane. Secreted. Note=Present at the cell surface of neuron cells. The membrane-associated isoform is approximately 5 kDa larger than the known cytosolic isoform.
Protein Families
Peptidase M16 family
Tissue Specificity
Detected in brain and in cerebrospinal fluid (at protein level).
Database Links

HGNC: 5381

OMIM: 146680

KEGG: hsa:3416

STRING: 9606.ENSP00000265986

UniGene: Hs.500546

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*